{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2(11)"],"submitter":["Angermann CE"],"pubmed_abstract":["Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve clinical outcomes in patients with heart failure (HF), but mechanisms of action are incompletely understood. In the EMPA-TROPISM trial, empagliflozin reversed cardiac remodeling and increased physical capacity in stable non-diabetic patients with systolic HF. Here we explore, post hoc, whether treatment effects in this cohort, comprising patients who had a high prevalence of iron deficiency, were related to iron metabolism. Myocardial iron content estimated by cardiac magnetic resonance T2* quantification increased after initiation of empagliflozin but not placebo (treatment effect: P = 0.01). T2* changes significantly correlated with changes in left ventricular volumes, mass and ejection fraction, peak oxygen consumption and 6-min"],"journal":["Nature cardiovascular research"],"pagination":["1032-1043"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11358002"],"repository":["biostudies-literature"],"pubmed_title":["Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure."],"pmcid":["PMC11358002"],"pubmed_authors":["Zeller T","Frantz S","Requena-Ibanez JA","Maack C","Sehner S","Santos-Gallego CG","Gerhardt LMS","Ertl G","Badimon JJ","Angermann CE","Sanz J","Fuster V"],"additional_accession":[]},"is_claimable":false,"name":"Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure.","description":"Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve clinical outcomes in patients with heart failure (HF), but mechanisms of action are incompletely understood. In the EMPA-TROPISM trial, empagliflozin reversed cardiac remodeling and increased physical capacity in stable non-diabetic patients with systolic HF. Here we explore, post hoc, whether treatment effects in this cohort, comprising patients who had a high prevalence of iron deficiency, were related to iron metabolism. Myocardial iron content estimated by cardiac magnetic resonance T2* quantification increased after initiation of empagliflozin but not placebo (treatment effect: P = 0.01). T2* changes significantly correlated with changes in left ventricular volumes, mass and ejection fraction, peak oxygen consumption and 6-min","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2026-06-02T09:13:02.817Z","creation":"2025-04-05T18:38:24.563Z"},"accession":"S-EPMC11358002","cross_references":{"pubmed":["39196095"],"doi":["10.1038/s44161-023-00352-5"]}}